A phase II trial of regorafenib in patients with metastatic and/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17

BACKGROUND: Gastrointestinal stromal tumors (GISTs) are caused by the constitutive activation of KIT or platelet-derived growth factor receptor alpha (PDGFRA) mutations. Imatinib selectively inhibits KIT and PDGFR, leading to disease control for 80%–90% of patients with metastatic GIST. Imatinib res...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Oncotarget
Glavni autori: Yeh, Chun-Nan, Chen, Ming-Huang, Chen, Yen-Yang, Yang, Ching-Yao, Yen, Chueh-Chuan, Tzen, Chin-Yuan, Chen, Li-Tzong, Chen, Jen-Shi
Format: Artigo
Jezik:Inglês
Izdano: Impact Journals LLC 2017
Teme:
Research Paper
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5546467/
https://ncbi.nlm.nih.gov/pubmed/28487491
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.17310
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items